Conditions

Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?

In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana's weight loss benefits may also apply to people who don't have diabetes.

In this week's Homerun Slides, the Canadian Diabetes Association's guidelines for the pharmacologic treatment of type 2 diabetes, which dictate that the choice of therapy depends on glycemia.

Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.

Study suggests wine consumption offers greater protection against type 2 risk, compared with beer or other alcoholic beverages.

In this week's Homerun Slides, the cost of the current diabetes classification.

New guidelines cite effectiveness, cost efficiency, and safety as reasons to consider procedure.

Higher level of cardiorespiratory fitness (CRF) over two decades was shown to reduce risk for developing prediabetes and T2, even after adjusting for changes in BMI.

A recent study published in Obesity in May 2016 reported very discouraging findings for a group of participants who had lost weight on “The Biggest Loser” (TBL) reality TV show: not only did almost all of them regain a significant amount of weight over the 6-year period following the show, but they also had lower resting metabolic rates than expected for their body weights, even six years later. With the way the media ran with this story, it will not be a surprise if everyone just gives up staying thinner and blames excess weight on a faulty, and unchangeable, metabolism.

In this week's Homerun Slides, potential new treatment guidelines inspired by beta-cell-centric classification of diabetes.